Single Biggest Cancer Dictionary in the World

What is

EGFR/HER2 mutant-selective inhibitor BAY2927088

?

Pronunciation: /egfr* hər tu mˈjutənt səˈlɛktɪv ˌɪnˈhɪbətər beɪ tu ˈmɪljən, naɪn ˈhənərd ənd twenty-seven* ˈθaʊzənd ənd eighty-eight*/

EGFR/HER2 mutant-selective inhibitor BAY2927088

Definition

An orally bioavailable, mutant-selective, dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), with potential antineoplastic activity. Upon oral administration, EGFR/HER2 mutant-selective inhibitor BAY2927088 targets, binds to, and inhibits the activity of EGFR and HER2 with exon20 insertion mutations, as well as EGFR with C797X mutations, thereby preventing EGFR- and HER2-mediated signaling. This may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization.